To the Editor-We have previously reported an association between IgG2 deficiency and severe H1N1 infection [1] . We now describe 5 such patients who were failing antiviral therapy and were treated with intravenous immunoglobulin (IVIG) as potential salvage therapy.
The patient clinical characteristics, laboratory features, treatment, tolerability, and overall outcomes are described in Table 1 . All patients had known risk factors for severe H1N1 infection (pregnancy, n 5 2; asthma, n 5 1; obesity and asthma, n 5 1; chronic lymphocytic leukemia plus high-dose corticosteroids, n 5 1). All patients required mechanical ventilation (mean, 19 days; range, 5-38 days) and 3 required extracorporeal membrane oxygenation (ECMO; mean, 13 days; range, 9-17 days). IVIG was administered after mean illness duration of 11 days (range, 8-17 days) and after a mean of 5 days (range, 2-12 days) of antiviral therapy. Two commercial preparations (Intragam by CSL; Australian donors, or Octagam by Octapharma; European donors) and various doses of IVIG (0.25-1 g/kg) were used due to limited availability. Notably, among all 3 patients who received EC-MO, IgG2 levels remained in the deficient range following IVIG, raising the possibility of an interaction (eg, destruction or binding) between the EC-MO circuit and immunoglobulin. Two patients (patients 4 and 5) received intravenous zanamivir in addition to IVIG (for details, see Table 1 ). This is the first report to our knowledge of patients with IgG2 deficiency and H1N1 pneumonitis being treated with IVIG. However, because of the heterogeneity of illness duration and severity, and the possible differences in IVIG regimens, we cannot be certain of the therapeutic benefit of IVIG, although in a number of our patients (patients 1, 2, and 4) its administration seemed to be associated with improvement. Of concern, however, 2 patients (patients 2 and 3) had significant respiratory deterioration following IVIG, and although we were unable to determine if the deterioration was due to progression of influenza pneumonitis or a complication of IVIG, it is prudent to consider the previous reports of potential adverse effects of IVIG therapy in patients with extensive pulmonary injury [2] .
Despite advances in intensive care and antiviral medication, the mortality for critically ill patients with H1N1 is up to 15% [3] and alternative therapies are needed. Influenza-specific passive immunotherapy with convalescent plasma, hyperimmune immunoglobulin, or monoclonal antibodies has gained support by some as potential treatment for influenza [2] and may be particularly important in patients with IgG2 deficiency. Convalescent blood products used during the Spanish influenza pandemic reduced mortality [4] , and success against H5N1 influenza has been reported [5] . We were unable to assess H1N1-specific antibodies in our IVIG; however, cross-reactive neutralizing antibody against 2009 H1N1 has recently been described in IVIG preparations [6, 7] .
From this small case series of IgG2-deficient patients with extremely severe H1N1 infection, we believe IVIG therapy may be beneficial in some but not all patients; that it does not appear to have any long-term adverse effects; but that for some patients there may be a transient period of mild deterioration during the 48 h immediately after IVIG administration. We believe IVIG therapy deserves additional evaluation among critically ill patients with H1N1 infection. b Second dose of IVIG given c Sequencing of neuraminidase in this strain of H1N1 did not reveal a mutation at the H275 residue nor any other changes in the neuraminidase sequence that would affect oseltamivir susceptibility. Steady state serum trough oseltamivir carboxylate concentrations (541 ng/mL and greater) were well above concentrations achieved in healthy subjects (approximately 300 ng/mL), suggesting effective nasogastric absorption of oseltamivir [8] . Because of the perceived poor clinical efficacy of oseltamivir, intravenous zanamivir was commenced.
d Third dose of IVIG given e Fresh frozen plasma given f Hand ventilated with bag and mask g A modified Sequential Organ Failure Assessment (SOFA) score was used to remove the confounding effect of the neurological component in sedated patients.
